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Abstract. Chloroquine-resistant Plasmodium vivax malaria is emerging in Oceania, Asia, and Latin America. We
assessed the drug sensitivity of P. vivax to chloroquine or halofantrine in two villages in southern, central Vietnam.
This area has chloroquine-resistant Plasmodium falciparum but no documented chloroquine-resistant P. vivax. Stan-
dard dose chloroquine (25 mg/kg, over 48 hours) or halofantrine (8 mg/kg, 3 doses) was administered to 29 and 25
patients, respectively. End points were parasite sensitivity or resistance determined at 28 days. Of the evaluable
patients, 23/23 100% (95% confidence interval [CI] 85.1–100) chloroquine and 21/24 (87.5%) (95% CI 67.6–97.3)
halofantrine-treated patients were sensitive. Three halofantrine recipients had initial clearance but subsequent recur-
rence of their parasitemias. Genotyping of the recurrent and Day 0 parasitemias differed, suggesting either new
infections or relapses of liver hypnozoites from antecedent infections. Among these Vietnamese patients, P. vivax
was sensitive to chloroquine and halofantrine. Genotyping was useful for differentiating the recurrent vivax parasit-
emias.
INTRODUCTION
Multidrug-resistant Plasmodium falciparum malaria is
well established in many malaria-endemic countries.1–3 Chlo-
roquine-resistant Plasmodium vivax (CRPV) is now emerg-
ing and has been reported in Papua New Guinea,4 India,5
Burma,6 Guyana,7 and Indonesia.8–13 Chloroquine-resistant
Plasmodium vivax is currently a significant public health
problem in Irian Jaya, where documented treatment failure
rates are as high as 78% at 28 days.12 Alternative drugs to
chloroquine are needed to treat chloroquine-resistant P. vi-
vax.
In vivo data from different malaria-endemic areas are of
prime importance for determining optimal treatment and pro-
phylaxis recommendations.14,15 The 28-day in vivo test is a
good method for defining parasite sensitivity but interpreta-
tion of recurrent parasitemia during follow-up is an inherent
problem because recrudescence, relapse of liver hypnozoites,
or a new infection cannot be clinically differentiated with
certainty. This difficulty can be alleviated by genotyping the
recurrent and Day 0 parasitemias. Previous studies indicate
that genotyping of Plasmodium species-specific polymorphic
genes by the polymerase chain reaction (PCR) utilizing sin-
gle-strand conformational polymorphism (SSCP) lysis tech-
niques can distinguish recrudescent from new infections with
a probability of  90% for P. falciparum,16,17 and  80%
for P. vivax.13,18
Measuring drug levels, e.g., by high performance liquid
chromatography (HPLC), adds further weight to the 28-day
in vivo test because it confirms whether adequate drug ab-
sorption has taken place—a prerequisite for meeting the
World Health Organization definition of drug-resistant ma-
laria.19
We report the results of treating patients with P. vivax
malaria in southern Vietnam to determine the efficacy of
chloroquine and assess halofantrine as a potential alternative
drug.
MATERIALS AND METHODS
Study design and study site. This was a 28-day in vivo
test to assess the drug sensitivity of P. vivax to chloroquine
or halofantrine. The study was conducted from May to Au-
gust 1995 in Khanh Nam and Khanh Vinh (Khang Hoa prov-
ince), two villages situated in an area of high malaria trans-
mission about 40 miles inland from the coastal town of Nha
Trang in southern, central Vietnam. Previous malariometric
surveys had shown malaria prevalence rates of between 25–
28% in adults and 30–40% in children  9 years (Nhan DH,
unpublished data). Chloroquine-resistant P. falciparum20 is
the dominant species at 60%; P. vivax and P. malariae ac-
count for 32% and 5%, respectively. Malaria incidence rates,
measured as infections per person-year, are 1.9 for P. falci-
parum, 1.1 for P. vivax, and 0.03 for P. malariae.
Written, informed consent was obtained from all partici-
pating patients or their parents/guardians. The study was
conducted according to the Vietnamese Ministry of Health
and the United States Navy regulations regarding the pro-
tection of human subjects in medical research.
Pre-study assessment. Potential volunteers were identi-
fied during village-wide screening or were self-referred.
Team physicians made medical assessments that consisted of
a history, a drug history (previous drug use within one
month, drug allergies), a physical examination, a malaria
film, a urine pregnancy test, and an electrocardiogram (ECG)
rhythm strip (lead II), supplemented by a 12 lead strip, if
clinically indicated. Eligible patients were healthy males or
non-pregnant females, aged  5 years, with slide-proven vi-
vax parasitemia, and a normal QTC interval on the ECG.
Specific exclusions included mixed malaria infections, age
 5 years, pregnant or breast-feeding women, known hy-
persensitivity to chloroquine or halofantrine, ingestion of
mefloquine in the previous two weeks, concurrent use of
drugs which prolong the QT interval, clinical cardiac dis-
ease, and a QTC of  0.44 ms.
Conduct of study. Enrolled patients were classified as
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TABLE 1
Patient characteristics at enrollment
Halofantrine
(n  25)
Chloroquine
(n  29)
No. (%) males
Median (range) age, years
Prestudy antimalarial drug use*
No. (%) symptomatic†
No. (%) febrile‡
No. (%) with splenomegaly
Median parasitemia/l (range)§
12 (48)
15 (5-55)
7 (28)
24 (96)
16 (64)
6 (25)
140 (40–6,360)
14 (48.3)
14 (5-40)
6 (20.7)
23 (79.3)
14 (48.3)
9 (31)
440 (40–34,920)
* Number (%) consuming any antimalarial drug within one month of enrollment.
† Defined as fever or chills or headache or myalgia.
‡ Defined as an oral temperature 37.0C.
st P  0.086, by Mann-Whitney U test.
symptomatic if complaining of at least one of the following
symptoms: fever, chills, headache, or myalgia. Because this
was not a comparative clinical trial, there were no predeter-
mined criteria for patient randomization/study drug admin-
istration. Standard dose chloroquine (Avloclor, Zeneca) was
administered in the clinic and at home: 10 mg chloroquine
base/kg on Days 0 and 1, and 5 mg/kg on Day 2. Subjects
who received halofantrine (SmithKline Beecham, UK) were
admitted into hospital for one day. Halofantrine, at a dose
of 8 mg/kg, was administered three times at 6 hourly inter-
vals on an empty stomach or at least one hour before, or
two hours after, a meal. All drug doses were administered
and documented by a team member.
Follow-up thick and thin film blood smears were Giemsa-
stained and examined for malaria parasites by experienced
microscopists on Days 1, 2, 4, 7, 11, 14, 18, 21, and 28, or
the day of recurrent parasitemia. A positive smear was de-
fined as one or more asexual forms seen after examining 200
thick film fields under 1000  magnification. The parasite
count was quantified as the number of asexual parasites per
200 white blood cells on the thick film, multiplied by 40,
and expressed as parasites/L.21
Whole blood specimens (100 l) were collected by finger
stick with a capillary tube and blotted on filter paper (No. 1
Whatman, Fairfield, NJ) for chloroquine drug levels, and
fiber glass filter paper (Titetek, UK) for PCR analysis, on
Days 0 (predrug administration), 2, and 28, or the day of
recurrent parasitemia. Blots were air dried and stored in in-
dividual plastic bags at ambient temperature until analysed.
Chloroquine and desethylchloroquine (the main active me-
tabolite of chloroquine) were measured by HPLC, according
to published methods.22 Chloroquine concentrations (ng/mL)
are reported as whole blood total chloroquine (TCQ) i.e., the
sum of chloroquine (CQ) and desethylchloroquine
(desethylCQ).
Genotyping by PCR. Parasite DNA was extracted from
whole blood from the three paired specimens (the primary
and recurrent isolates). A portion of the MSP1 and CS genes
were amplified by PCR using oligonucleotide primers
matching the conserved sequences flanking the variable re-
gion ICB5–ICB6 of the MSP1 gene and region I and II of
the CS gene as previously described.18 The paired primary
and recurrent MSP1 PCR products were analysed by SSCP.
MSP1 PCR products were analysed with and without Rsa 1
enzyme digestion (New England Biolabs, Mississauga, ON,
Canada). Following digestion, chloroform extraction, and
ethanol precipitation, each sample was resuspended in 9 l
of sterile water. PCR products were denatured prior to SSCP
analysis by adding 1 L of 0.5 mM NaOH/10 mM EDTA
to 100–200 ng of amplified DNA in 9 l of sterile water,
followed by heating at 42C for 5 mins. Loading buffer
(0.5% bromophenol blue, formamide, and glycerol) was add-
ed and each sample was placed on ice before electrophoresis
on a nondenaturing 10% TBE polyacrylamide minigel (1
mm; Novex, San Diego CA). Lanes containing 1 kilobyte
(kb) DNA markers or reference strains that had been simi-
larly treated, were used to standardize SSCP patterns. Sam-
ples were run under constant voltage with 0.8X glycerol tol-
erant running buffer (USB, Cleveland, OH), and 5% glycerol
for 2250 volt-hr (MSP1 undigested samples), 1500 volt-hr
(digested MSP1), or 2625 volt-hr (CS). SSCP banding pat-
terns were detected by silver staining (Bio-Rad, Hercules
CA). Digested MSP1 DNA fragment SSCP patterns were
scanned, digitalized, and analysed using the BioImage Sys-
tem with Whole Band Analysis, Version 3 (Millipore Corp.,
Ann Arbor, MI). The SSCP patterns of the recurrent isolates
were compared to each of the primary isolates.
Our criterion for identity was that the mobility of the
SSCP band of the recurrent isolate had to match the corre-
sponding band of the primary (Day 0) isolate; this would
indicate a treatment failure or a relapse of the current infec-
tion.13,18,23 Non-identity would indicate a new infection or
relapse of liver hypnozoites of an antecedent infection.
End points. The parasitological end points were classified
as either sensitive (S) or resistant (R). Sensitive  the com-
plete clearance of asexual parasitemia to Day 28. Resistant
 failure to clear parasitemia or recurrence of the original
parasitemia (assessed by PCR) following initial clearance.
Data analysis. Data were double-entered, validated, and
analysed using Epi Info 6.04 (Centers for Disease Control
and Prevention, Atlanta, GA). Continuous data were com-
pared using the student’st (normal distribution) or the Mann-
Whitney U tests (skewed distribution). A two-sided P value
 0.05 was considered statistically significant.
RESULTS
A total of 54 patients were treated, 29 with chloroquine
and 25 with halofantrine (H); their enrollment characteristics
are detailed in Table 1. A minority of patients, 13/54
(24.1%), gave a history of consuming an antimalarial drug
in the previous month. During follow-up, 3 patients default-
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FIGURE 1. Polymerase chain reaction utilizing single-strand conformational polymorphism (SSCP) analysis of the MSP-1 gene from the
Day 0 and recurrent vivax isolates showing a mismatch between the SSCP patterns (Panel A: Lanes 2–3 and 4–5). Previously confirmed
primary and resistant Plasmodiium vivax pairs are shown as controls (Panel A: Lanes 6–7, Panel B: Lanes 2–3, and 4–5).
ed (CQ arm), 4 developed falciparum malaria (3 in CQ arm
and 1 in H arm), and 3 had recurrent parasitemia (H arm).
These recurrences occurred on Days 14, 25, and 28 in pa-
tients aged 5, 23, and 24 years, respectively. Of the remain-
ing patients, 23/23 (100%) (95% CI 85.1–100) chloroquine
recipients and 21/24 (87.5%) (95% CI 67.6–97.3) halofan-
trine recipients cleared their parasitemias. On Day 0, 4 sam-
ples had high levels of chloroquine (170–466 ng/mL) but
undetectable desethylCQ, consistent with contamination.
These four values were excluded from further CQ analyses.
The median Day 0 TCQ in 25 CQ-treated patients was 36
(range 0–1038) ng/mL. Sixteen had detectable CQ and
twelve had TCQ concentrations  100 ng/mL, median 511.5
(range 115–1038) ng/mL. The median parasite counts of
these 12 patients on Day 0 were higher (1240l) than pa-
tients with a TCQ  100 ng/mL (320l) but this difference
was not statistically significant (P  0.34). TCQ concentra-
tions measured on Day 2 showed marked inter-individual
variation, ranging from 517–7020 ng/ml (median 1132 ng/
ml). There was no correlation between the Day 2 and Day
0 TCQ levels: r2  0.0 (95% CI, 0.42–0.43). The day 28
median TCQ concentration (n  22) was 139.5 (24–530)
ng/mL; 14 patients (63.6%) had a TCQ  100g/mL. No
correlation existed between the Day 28 and Day 2 TCQ lev-
els: r2  0.0 (95% CI, 0.44–0.44).
The PCR-SSCP analysis of the MSP-1 gene from primary
and recurrent isolates from patients treated with halofantrine
demonstrated that in all three paired isolates, the SSCP pat-
tern of the recurrent vivax isolate did not match the primary
isolate. The results of two of the halofantrine patients are
shown in Figure 1 (Panel A, Lanes 2–3 and 4–5). Previously
confirmed, paired primary and resistant P. vivax isolates are
included as controls (Panel A: Lanes 6–7, Panel B: Lanes
2–3 and 4–5).
DISCUSSION
This 28-day in vivo study has shown that in this group of
patients from southern, central Vietnam, P. vivax was sen-
sitive to chloroquine and halofantrine. However, three hal-
ofantrine-treated patients had recurrent parasitemia that, on
the basis of the PCR results, were unlikely to represent re-
sistant infections.
Our study was a non-comparative, 28-day in vivo test to
determine the sensitivity of P. vivax to chloroquine, an in-
effective drug against P. vivax in some endemic countries,
and halofantrine, an effective drug against multidrug-resis-
tant P. falciparum,24 and chloroquine-resistant P. vivax.7,12
While the 28-day in vivo test provides useful data on parasite
drug sensitivity, a vivax parasitemia occurring during fol-
low-up could be due to a new infection, a recrudescence of
the original infection, or a relapse of liver hypnozoites of
the current or an antecedent infection. With an incidence rate
of 1 vivax infection/person-year in the study villages, the
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expected number of new vivax infections in 54 patients fol-
lowed for one month is 3.25. This figure is consistent with
our three cases of recurrent parasitemia, demonstrating that
reinfections were a minor confounding factor in this study.
PCR genotyping showed these three recurrent parasitemias
to be different from their respective Day 0 parasitemias and
is strong supporting evidence that they were not resistant
infections but were either new infections or relapses of an-
tecedent infections. In studies of P. vivax in Indonesia,13 and
of returned expatriates to Canada,7,18 matching fingerprints
of recurrent and Day 0 parasitemias had a  80% probability
of indicating either resistance or relapse (Kain K, unpub-
lished data). The recurrent parasitemias in our patients oc-
curred on Days 14, 25, and 28 of follow-up. At these times
the concentrations of halofantrine and N-desbutylhalofantri-
ne (its major metabolite) would have been low or nonexis-
tent given that their measured half lives are in the range of
1–6 days in patients with P. falciparum malaria.26,27
The measurement of drug levels to document adequate
absorption (in this field study only chloroquine levels were
measured) provides the pharmacological basis for interpret-
ing the 28-day in vivo test. Failure to completely clear par-
asites after documenting adequate drug absorption is evi-
dence of resistance19 and distinguishes it from treatment fail-
ure due to other causes (i.e., poor compliance).
Determining the therapeutic range of chloroquine against
P. vivax is problematic because of the changing sensitivity
of P. vivax to chloroquine over time. In 1948, the chloro-
quine concentration required to cure patients with P. vivax
malaria was the equivalent of a mean, whole blood, total
chloroquine concentration of 100 ng/mL over 4 days.28 This
level was achieved with chloroquine doses of 275–650 mg
(4–10 mg/kg for a 70kg adult). In Sweden in 1987, stan-
dard dose chloroquine (25 mg/kg) cured all 15 adults with
non P. falciparum malaria (P. vivax, P. ovale, and P. ma-
lariae). The minimum whole blood TCQs were 1.76 mol/
L (528.5 ng/mL) at 48 hours, 1.48 mol/L (444.4 ng/
mL) on Day 4, and 1.09 mol/L (327.3 ng/ml) on Day 7.29
We measured the Day 2 (48 hr) TCQ concentration to
indicate adequate chloroquine absorption because this rep-
resents the approximate time of peak absorption (Tmax) of
standard-dose chloroquine.29 The lowest Day 2 total chlo-
roquine concentration was 517 ng/mL, but this value was
sufficient to produce a satisfactory pharmacokinetic profile
of chloroquine to kill vivax parasites in this group of Viet-
namese patients for up to 28 days. However, this value may
not be applicable to patients in other geographical areas.30
In Indonesia, adequately absorbed standard-dose chloro-
quine, documented by Day 2 TCQ levels similar to our
study, failed to cure all patients with vivax malaria.8,10–12,31,32
In these studies, a recurrent parasitemia, whether a recru-
descence, relapse, or new infection that occurred in the pres-
ence of a whole blood TCQ  100 ng/mL, was considered
resistant.
On Day 0, 12 chloroquine-treated patients had total chlo-
roquine levels of  100 ng/mL (median 511.5, range 115–
1038). Some of these parasites might have been resistant to
chloroquine at doses used by Berliner or to CQ prophylaxis;
300 mg of chloroquine weekly produced median TCQ levels
of 710–263 ng/mL over 7 days.33 However, all 12 patients
had sustained parasite clearance to 28 days, confirming sen-
sitivity to standard dose chloroquine (25 mg/kg). On Day
28, approximately two-thirds of patients had TCQ levels of
 100 ng/mL, high enough to exert a prophylactic effect
against sensitive vivax parasites.
In Vietnam, artemisinin34 and artesunate combined with
mefloquine35 have been used to treat vivax malaria. These
drugs produced very rapid fever and parasite clearance times
but recurrent parasitemia occurred in some patients treated
with shorter courses of artemisinin—an inherent problem
with this class of antimalarial drug.36 The optimal dose of
oral artesunate monotherapy for vivax malaria is unknown
but 7 days is likely to be necessary, as for falciparum ma-
laria.36 Use of such a valuable class of antimalarial drug is
not justified for the treatment of chloroquine-sensitive vivax
malaria.36 The artemisinins, as monotherapy or in combina-
tions, have become the treatment of choice in some South-
east Asian countries where multidrug resistant P. falciparum
malaria exists. In the absence of a microscopical diagnosis,
blind treatment with an artemisinin would be satisfactory for
both falciparum and vivax malaria. In areas where micros-
copy is available and the patterns of drug resistance are
known, treatment can be tailored accordingly. The optimal
treatment for chloroquine-resistant P. vivax is unknown. In
Vietnam, the artemisinins would be an obvious choice be-
cause of their high efficacy, safety, and low cost (US$1
per adult course). Halofantrine is efficacious against chlo-
roquine-resistant P. vivax7,12 but can cause potentially serious
cardiac arrhythmias, and is expensive (UK retail price
US$10 for three 500 mg tablets).24 Halofantrine may have
a role against chloroquine-resistant P. vivax in countries
where the artemisinins are not yet available.
To summarize, this 28-day in vivo test conducted in two
villages of southern, central Vietnam found evidence of re-
duced sensitivity of P. vivax to chloroquine but no clinical
resistance to therapeutic doses of chloroquine or halofan-
trine. Continuing surveillance is required to see whether this
area becomes a focus of chloroquine-resistant P. vivax in the
future.
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